A concern regarding the use of a GLP-1RA in patients with T1D in clinical practice would be the risk of hypoglycemia, as GLP-1RAs not only enhance endogenous insulin secretion but also suppress glucagon release [55], a major counter-regulatory hormone. This evidence concerns the gene INS and Hypoglycemia.